Pediatric and adolescent extracranial germ cell tumors: The road to collaboration

Thomas A. Olson, Matthew J. Murray, Carlos Rodriguez-Galindo, James C. Nicholson, Deborah F. Billmire, Mark D. Krailo, Ha M. Dang, James F. Amatruda, Claire M. Thornton, G. Suren Arul, Sara J. Stoneham, Farzana Pashankar, Daniel Stark, Furqan Shaikh, David M. Gershenson, Allan Covens, Jean Hurteau, Sally P. Stenning, Darren R. Feldman, Peter S. GrimisonRobert A. Huddart, Christopher Sweeney, Thomas Powles, Luiz Fernando Lopes, Simone Dos Santos Agular, Girish Chinnaswamy, Sahar Khaleel, Sherif Abouelnaga, Juliet P. Hale, A. Lindsay Frazier

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

During the past 35 years, survival rates for children with extracranial malignant germ cell tumors (GCTs) have increased significantly. Success has been achieved primarily through the application of platinum-based chemotherapy regimens; however, clinical challenges in GCTs remain. Excellent outcomes are not distributed uniformly across the heterogeneous distribution of age, histologic features, and primary tumor site. Despite good outcomes overall, the likelihood of a cure for certain sites and histologic conditions is less than 50%. In addition, there are considerable long-term treatment-related effects for survivors. Even modest cisplatin dosing can cause significant long-term morbidities. A particular challenge in designing new therapies for GCT is that a variety of specialists use different risk stratifications, staging systems, and treatment approaches for three distinct age groups (childhood, adolescence, and young adulthood). Traditionally, pediatric cancer patients younger than 15 years have been treated by pediatric oncologists in collaboration with their surgical specialty colleagues. Adolescents and young adults with GCTs often are treated by medical oncologists, urologists, or gynecologic oncologists. The therapeutic dilemma for all is how to best define disease risk so that therapy and toxicity can be appropriately reduced for some patients and intensified for others. Further clinical and biologic insights can only be achieved through collaborations that do not set limitations by age, sex, and primary tumor site. Therefore, international collaborations, spanning different cooperative groups and disciplines, have been developed to address these challenges.

Original languageEnglish (US)
Pages (from-to)3018-3028
Number of pages11
JournalJournal of Clinical Oncology
Volume33
Issue number27
DOIs
StatePublished - Sep 20 2015

Fingerprint

Germ Cell and Embryonal Neoplasms
Pediatrics
Surgical Specialties
Therapeutics
Neoplasms
Age Distribution
Platinum
Cisplatin
Survivors
Young Adult
Survival Rate
Age Groups
Morbidity
Drug Therapy
Oncologists

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Olson, T. A., Murray, M. J., Rodriguez-Galindo, C., Nicholson, J. C., Billmire, D. F., Krailo, M. D., ... Frazier, A. L. (2015). Pediatric and adolescent extracranial germ cell tumors: The road to collaboration. Journal of Clinical Oncology, 33(27), 3018-3028. https://doi.org/10.1200/JCO.2014.60.5337

Pediatric and adolescent extracranial germ cell tumors : The road to collaboration. / Olson, Thomas A.; Murray, Matthew J.; Rodriguez-Galindo, Carlos; Nicholson, James C.; Billmire, Deborah F.; Krailo, Mark D.; Dang, Ha M.; Amatruda, James F.; Thornton, Claire M.; Arul, G. Suren; Stoneham, Sara J.; Pashankar, Farzana; Stark, Daniel; Shaikh, Furqan; Gershenson, David M.; Covens, Allan; Hurteau, Jean; Stenning, Sally P.; Feldman, Darren R.; Grimison, Peter S.; Huddart, Robert A.; Sweeney, Christopher; Powles, Thomas; Lopes, Luiz Fernando; Dos Santos Agular, Simone; Chinnaswamy, Girish; Khaleel, Sahar; Abouelnaga, Sherif; Hale, Juliet P.; Frazier, A. Lindsay.

In: Journal of Clinical Oncology, Vol. 33, No. 27, 20.09.2015, p. 3018-3028.

Research output: Contribution to journalArticle

Olson, TA, Murray, MJ, Rodriguez-Galindo, C, Nicholson, JC, Billmire, DF, Krailo, MD, Dang, HM, Amatruda, JF, Thornton, CM, Arul, GS, Stoneham, SJ, Pashankar, F, Stark, D, Shaikh, F, Gershenson, DM, Covens, A, Hurteau, J, Stenning, SP, Feldman, DR, Grimison, PS, Huddart, RA, Sweeney, C, Powles, T, Lopes, LF, Dos Santos Agular, S, Chinnaswamy, G, Khaleel, S, Abouelnaga, S, Hale, JP & Frazier, AL 2015, 'Pediatric and adolescent extracranial germ cell tumors: The road to collaboration', Journal of Clinical Oncology, vol. 33, no. 27, pp. 3018-3028. https://doi.org/10.1200/JCO.2014.60.5337
Olson TA, Murray MJ, Rodriguez-Galindo C, Nicholson JC, Billmire DF, Krailo MD et al. Pediatric and adolescent extracranial germ cell tumors: The road to collaboration. Journal of Clinical Oncology. 2015 Sep 20;33(27):3018-3028. https://doi.org/10.1200/JCO.2014.60.5337
Olson, Thomas A. ; Murray, Matthew J. ; Rodriguez-Galindo, Carlos ; Nicholson, James C. ; Billmire, Deborah F. ; Krailo, Mark D. ; Dang, Ha M. ; Amatruda, James F. ; Thornton, Claire M. ; Arul, G. Suren ; Stoneham, Sara J. ; Pashankar, Farzana ; Stark, Daniel ; Shaikh, Furqan ; Gershenson, David M. ; Covens, Allan ; Hurteau, Jean ; Stenning, Sally P. ; Feldman, Darren R. ; Grimison, Peter S. ; Huddart, Robert A. ; Sweeney, Christopher ; Powles, Thomas ; Lopes, Luiz Fernando ; Dos Santos Agular, Simone ; Chinnaswamy, Girish ; Khaleel, Sahar ; Abouelnaga, Sherif ; Hale, Juliet P. ; Frazier, A. Lindsay. / Pediatric and adolescent extracranial germ cell tumors : The road to collaboration. In: Journal of Clinical Oncology. 2015 ; Vol. 33, No. 27. pp. 3018-3028.
@article{feea99aaf6b2471f9ad70dbb976db084,
title = "Pediatric and adolescent extracranial germ cell tumors: The road to collaboration",
abstract = "During the past 35 years, survival rates for children with extracranial malignant germ cell tumors (GCTs) have increased significantly. Success has been achieved primarily through the application of platinum-based chemotherapy regimens; however, clinical challenges in GCTs remain. Excellent outcomes are not distributed uniformly across the heterogeneous distribution of age, histologic features, and primary tumor site. Despite good outcomes overall, the likelihood of a cure for certain sites and histologic conditions is less than 50{\%}. In addition, there are considerable long-term treatment-related effects for survivors. Even modest cisplatin dosing can cause significant long-term morbidities. A particular challenge in designing new therapies for GCT is that a variety of specialists use different risk stratifications, staging systems, and treatment approaches for three distinct age groups (childhood, adolescence, and young adulthood). Traditionally, pediatric cancer patients younger than 15 years have been treated by pediatric oncologists in collaboration with their surgical specialty colleagues. Adolescents and young adults with GCTs often are treated by medical oncologists, urologists, or gynecologic oncologists. The therapeutic dilemma for all is how to best define disease risk so that therapy and toxicity can be appropriately reduced for some patients and intensified for others. Further clinical and biologic insights can only be achieved through collaborations that do not set limitations by age, sex, and primary tumor site. Therefore, international collaborations, spanning different cooperative groups and disciplines, have been developed to address these challenges.",
author = "Olson, {Thomas A.} and Murray, {Matthew J.} and Carlos Rodriguez-Galindo and Nicholson, {James C.} and Billmire, {Deborah F.} and Krailo, {Mark D.} and Dang, {Ha M.} and Amatruda, {James F.} and Thornton, {Claire M.} and Arul, {G. Suren} and Stoneham, {Sara J.} and Farzana Pashankar and Daniel Stark and Furqan Shaikh and Gershenson, {David M.} and Allan Covens and Jean Hurteau and Stenning, {Sally P.} and Feldman, {Darren R.} and Grimison, {Peter S.} and Huddart, {Robert A.} and Christopher Sweeney and Thomas Powles and Lopes, {Luiz Fernando} and {Dos Santos Agular}, Simone and Girish Chinnaswamy and Sahar Khaleel and Sherif Abouelnaga and Hale, {Juliet P.} and Frazier, {A. Lindsay}",
year = "2015",
month = "9",
day = "20",
doi = "10.1200/JCO.2014.60.5337",
language = "English (US)",
volume = "33",
pages = "3018--3028",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "27",

}

TY - JOUR

T1 - Pediatric and adolescent extracranial germ cell tumors

T2 - The road to collaboration

AU - Olson, Thomas A.

AU - Murray, Matthew J.

AU - Rodriguez-Galindo, Carlos

AU - Nicholson, James C.

AU - Billmire, Deborah F.

AU - Krailo, Mark D.

AU - Dang, Ha M.

AU - Amatruda, James F.

AU - Thornton, Claire M.

AU - Arul, G. Suren

AU - Stoneham, Sara J.

AU - Pashankar, Farzana

AU - Stark, Daniel

AU - Shaikh, Furqan

AU - Gershenson, David M.

AU - Covens, Allan

AU - Hurteau, Jean

AU - Stenning, Sally P.

AU - Feldman, Darren R.

AU - Grimison, Peter S.

AU - Huddart, Robert A.

AU - Sweeney, Christopher

AU - Powles, Thomas

AU - Lopes, Luiz Fernando

AU - Dos Santos Agular, Simone

AU - Chinnaswamy, Girish

AU - Khaleel, Sahar

AU - Abouelnaga, Sherif

AU - Hale, Juliet P.

AU - Frazier, A. Lindsay

PY - 2015/9/20

Y1 - 2015/9/20

N2 - During the past 35 years, survival rates for children with extracranial malignant germ cell tumors (GCTs) have increased significantly. Success has been achieved primarily through the application of platinum-based chemotherapy regimens; however, clinical challenges in GCTs remain. Excellent outcomes are not distributed uniformly across the heterogeneous distribution of age, histologic features, and primary tumor site. Despite good outcomes overall, the likelihood of a cure for certain sites and histologic conditions is less than 50%. In addition, there are considerable long-term treatment-related effects for survivors. Even modest cisplatin dosing can cause significant long-term morbidities. A particular challenge in designing new therapies for GCT is that a variety of specialists use different risk stratifications, staging systems, and treatment approaches for three distinct age groups (childhood, adolescence, and young adulthood). Traditionally, pediatric cancer patients younger than 15 years have been treated by pediatric oncologists in collaboration with their surgical specialty colleagues. Adolescents and young adults with GCTs often are treated by medical oncologists, urologists, or gynecologic oncologists. The therapeutic dilemma for all is how to best define disease risk so that therapy and toxicity can be appropriately reduced for some patients and intensified for others. Further clinical and biologic insights can only be achieved through collaborations that do not set limitations by age, sex, and primary tumor site. Therefore, international collaborations, spanning different cooperative groups and disciplines, have been developed to address these challenges.

AB - During the past 35 years, survival rates for children with extracranial malignant germ cell tumors (GCTs) have increased significantly. Success has been achieved primarily through the application of platinum-based chemotherapy regimens; however, clinical challenges in GCTs remain. Excellent outcomes are not distributed uniformly across the heterogeneous distribution of age, histologic features, and primary tumor site. Despite good outcomes overall, the likelihood of a cure for certain sites and histologic conditions is less than 50%. In addition, there are considerable long-term treatment-related effects for survivors. Even modest cisplatin dosing can cause significant long-term morbidities. A particular challenge in designing new therapies for GCT is that a variety of specialists use different risk stratifications, staging systems, and treatment approaches for three distinct age groups (childhood, adolescence, and young adulthood). Traditionally, pediatric cancer patients younger than 15 years have been treated by pediatric oncologists in collaboration with their surgical specialty colleagues. Adolescents and young adults with GCTs often are treated by medical oncologists, urologists, or gynecologic oncologists. The therapeutic dilemma for all is how to best define disease risk so that therapy and toxicity can be appropriately reduced for some patients and intensified for others. Further clinical and biologic insights can only be achieved through collaborations that do not set limitations by age, sex, and primary tumor site. Therefore, international collaborations, spanning different cooperative groups and disciplines, have been developed to address these challenges.

UR - http://www.scopus.com/inward/record.url?scp=84942235183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942235183&partnerID=8YFLogxK

U2 - 10.1200/JCO.2014.60.5337

DO - 10.1200/JCO.2014.60.5337

M3 - Article

C2 - 26304902

AN - SCOPUS:84942235183

VL - 33

SP - 3018

EP - 3028

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 27

ER -